Amplia Therapeutics Limited (ASX:ATX)

John Lambert
MD & CEO
Market Cap (AUD): 19.01M
Sector: Health Care
Last Trade (AUD): 0.098 +0 (+0%)
Tab Bar

1. About

Amplia Therapeutics Limited (ASX:ATX) is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. 

FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic cancer. 

FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

2. Business model

3. Strategy

4. Markets

5. Competition

6. History

7. Team

8. Financials

9. Risk